Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Maintenance dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,859 result(s) found for: Maintenance dose. Displaying page 1 of 93.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-002549-13 Sponsor Protocol Number: CSUC-01/21 Start Date*: 2021-09-07
    Sponsor Name:InDex Pharmaceuticals
    Full Title: A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants with Moderate to ...
    Medical condition: Moderate to Severe left-sided Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Ongoing) HU (Prematurely Ended) FR (Prematurely Ended) SK (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) NO (Prematurely Ended) BE (Completed) DK (Prematurely Ended) HR (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002531-27 Sponsor Protocol Number: EMN30/64007957MMY3003 Start Date*: 2022-04-11
    Sponsor Name:European Myeloma Network (EMN)
    Full Title: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following ...
    Medical condition: Newly Diagnosed Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) IT (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) IE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023407-95 Sponsor Protocol Number: MO25455 Start Date*: 2011-10-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin’s lympho...
    Medical condition: Patients with relapsed or refractory CD20+ follicular non-Hodgkin’s lymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma, marg...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000013103 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) SK (Completed) LT (Completed) HU (Completed) FR (Completed) ES (Completed) SI (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-001131-35 Sponsor Protocol Number: 08-0106-stop Start Date*: 2008-05-14
    Sponsor Name:Academic Medical Center, department of Gastroenterology and hepatology
    Full Title: Azathioprine maintenance treatment versus Infliximab maintenance treatment in Crohn's disease patients in remission: a randomized multicenter trial
    Medical condition: this study is designed as a multicenter radomized trial comparing azathioprine maintenance treatment to infliximab maintenance treatment in Crohn's disease patients that are in remission for at lea...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002926-67 Sponsor Protocol Number: 021048 Start Date*: 2005-12-16
    Sponsor Name:NV Organon
    Full Title: An open-label, randomized, phase IIIB, multicenter trial to evaluate the pharmacodynamic parameters of intubation bolus, and bolus and infusion maintenance doses of Zemuron® in pediatric and adoles...
    Medical condition: Not applicable
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002378-30 Sponsor Protocol Number: A3921210 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Inc.
    Full Title: OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Medical condition: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) SK (Completed) FR (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001199-12 Sponsor Protocol Number: MLN0002/CCT-001 Start Date*: 2019-05-28
    Sponsor Name:Takeda
    Full Title: Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induct...
    Medical condition: This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of intravenous Vedolizumab (300 mg) infusi...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004587-38 Sponsor Protocol Number: ESKETINTRD3004 Start Date*: 2015-08-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
    Medical condition: Treatment-resistant Major Depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed) ES (Completed) GB (Completed) AT (Completed) PL (Completed) BG (Completed) LT (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001924-37 Sponsor Protocol Number: D3250C00072 Start Date*: 2020-01-07
    Sponsor Name:AstraZeneca AB
    Full Title: SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever T...
    Medical condition: Severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004822-17 Sponsor Protocol Number: 17072008 Start Date*: 2008-12-10
    Sponsor Name:University Medical Center
    Full Title: Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patients
    Medical condition: Evaluation of the safety and efficacy of bortezomib combined with cyclophosphamide and dexametasone for induction and maintenance in bortezomib naive refractory on relapsed MM, stage II - III.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003824-36 Sponsor Protocol Number: GA29144 Start Date*: 2015-08-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATE...
    Medical condition: Crohn`s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) EE (Completed) LT (Completed) LV (Completed) HU (Completed) DE (Prematurely Ended) ES (Ongoing) CZ (Completed) NL (Completed) AT (Completed) SK (Completed) BE (Completed) FR (Completed) HR (Completed) RO (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000574-11 Sponsor Protocol Number: SHP647-304 Start Date*: 2018-03-13
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
    Medical condition: Ulcerative colitis or Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) AT (Completed) LT (Completed) CZ (Completed) NL (Completed) SK (Completed) BG (Completed) GR (Completed) PL (Completed) BE (Completed) ES (Completed) PT (Completed) EE (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-002136-24 Sponsor Protocol Number: 0157 Start Date*: 2019-09-10
    Sponsor Name:Theravance Biopharma Ireland Limited
    Full Title: A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with TD-1...
    Medical condition: Moderately-to-Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Completed) SK (Prematurely Ended) PT (Prematurely Ended) BG (Prematurely Ended) PL (Completed) GR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-000443-28 Sponsor Protocol Number: C3291035 Start Date*: 2020-03-27
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction with Crisaborole Ointment, 2%, Once Daily Over 52 Week...
    Medical condition: Mild-to-Moderate Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003640 Atopic dermatitis and related conditions LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003198-17 Sponsor Protocol Number: UZB_20160728 Start Date*: 2016-09-29
    Sponsor Name:Universitair Ziekenhuis Brussel Vrije Universiteit Brussel
    Full Title: A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome
    Medical condition: Treatment of Idiopathic Nephrotic Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002133-37 Sponsor Protocol Number: COR-2012-01 Start Date*: 2014-11-17
    Sponsor Name:Cortendo AB
    Full Title: An Open Label Study to Assess the Safety and Efficacy of COR—003 (2S, 4R-Ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome
    Medical condition: Endogenous Cushing's syndrome (CS) or Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) BE (Completed) NL (Completed) SE (Completed) DK (Completed) DE (Completed) IT (Completed) BG (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-001215-69 Sponsor Protocol Number: 69HCL17_0020 Start Date*: 2018-09-24
    Sponsor Name:Hospices Civils de Lyon
    Full Title: MAINEPSAN Study A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remission MAINtenance using Extended administration of ...
    Medical condition: Patients with newly diagnosed or relapsing granulomatosis with polyangiitis (GPA, Wegener’s) or microscopic polyangiitis (MPA) , 12 months after initiation of treatment for vasculitis onset or flar...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005276-14 Sponsor Protocol Number: RGCH004 Start Date*: 2016-06-03
    Sponsor Name:Sykehuset Østfold HF
    Full Title: Prolonging the response by low-dose Rituximab maintenance therapy in immune thrombocytopenia: a randomized placebo-controlled trial- the PROLONG trial.
    Medical condition: Immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DK (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001744-65 Sponsor Protocol Number: SPD476-319 Start Date*: 2014-10-22
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Paediatric Subjects with Mild to Moderate Ulcerative Colitis, in both Acu...
    Medical condition: Mild to Moderate Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) SK (Completed) NL (Prematurely Ended) PL (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002783-33 Sponsor Protocol Number: C13007 Start Date*: 2009-03-02
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn?s Dise...
    Medical condition: Moderate to Severe Crohn's Disease Enfermedad de Crohn moderada o grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) HU (Completed) SK (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) IS (Completed) PT (Prematurely Ended) DK (Completed) FR (Completed) BE (Completed) MT (Completed) GB (Completed) BG (Completed) SE (Completed) IT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 17:58:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA